Dyne Therapeutics Inc (DYN) concluded trading on Wednesday at a closing price of $10.78, with 4.36 million shares of worth about $46.98 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -69.41% during that period and on April 23, 2025 the price saw a gain of about 8.78%. Currently the company’s common shares owned by public are about 102.32M shares, out of which, 87.73M shares are available for trading.
Stock saw a price change of 37.32% in past 5 days and over the past one month there was a price change of -12.99%. Year-to-date (YTD), DYN shares are showing a performance of -54.24% which decreased to -54.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.36 but also hit the highest price of $47.45 during that period. The average intraday trading volume for Dyne Therapeutics Inc shares is 2.25 million. The stock is currently trading 20.43% above its 20-day simple moving average (SMA20), while that difference is down -4.43% for SMA50 and it goes to -59.27% lower than SMA200.
Dyne Therapeutics Inc (NASDAQ: DYN) currently have 102.32M outstanding shares and institutions hold larger chunk of about 80.95% of that.
The stock has a current market capitalization of $1.22B and its 3Y-monthly beta is at 1.20. It has posted earnings per share of -$3.35 in the same period. It has Quick Ratio of 15.60 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DYN, volatility over the week remained 11.11% while standing at 11.36% over the month.
Stock’s fiscal year EPS is expected to drop by -5.63% while it is estimated to decrease by -3.77% in next year. EPS is likely to grow at an annualized rate of 4.20% for next 5-years, compared to annual growth of -59.45% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on March 12, 2025 offering an Outperform rating for the stock and assigned a target price of $50 to it. Coverage by Scotiabank stated Dyne Therapeutics Inc (DYN) stock as a Sector outperform in their note to investors on March 07, 2025, suggesting a price target of $50 for the stock. On December 13, 2024, Robert W. Baird Initiated their recommendations, while on November 26, 2024, RBC Capital Mkts Initiated their ratings for the stock with a price target of $45. Stock get a Neutral rating from JP Morgan on October 24, 2024.
